Eli Lilly & Co (LLY) Shows Promising Signs of Uptrend Continuation
Eli Lilly & Co (LLY) is expected to maintain its upward trajectory, according to A.I.dvisor's predictions. With a projected growth of 2% to reach $451.18 or higher within the next week, the stock shows promising signs of an Uptrend continuation. This positive outlook is supported by a winning streak that has extended for consecutive weeks, indicating strong momentum.
Join our team and immerse yourself in the world of AI-driven trading with Eli Lilly & Co. Experience the power of our Bearish S&P 500 Swing Trader: one position only (TA), meticulously crafted using advanced technical analysis (TA) techniques.
With our AI-powered approach, we focus on identifying optimal swing trading opportunities within the S&P 500 index. Eli Lilly & Co has caught our attention as a bearish candidate, presenting an intriguing position for potential profits. By leveraging our cutting-edge technology, we have devised a strategy tailored to capitalize on this market sentiment.
One notable indicator that suggests further upside potential for LLY is the Aroon Indicator. On June 01, 2023, the AroonUp line crossed above 70, while the AroonDown line remained below 30. This bullish signal indicates that the stock may be setting up for a potential upward move. Traders may consider buying LLY or exploring call options to capitalize on this anticipated trend continuation. Looking at historical data, A.I.dvisor identified 353 similar instances where the Aroon Indicator exhibited a similar pattern, and in 240 of those cases, the stock moved higher in the subsequent days. This translates to an encouraging 68% probability of a move higher for LLY.
Furthermore, there is a notable correlation between LLY and MRK over the past year. These two tickers have shown a loose lockstep movement around 57% of the time. This statistical relationship suggests that if LLY experiences a jump in price, there is a possibility that MRK could also see price increases. Investors interested in LLY may want to keep an eye on MRK as well for potential opportunities.
As investors assess the prospects of Eli Lilly & Co (LLY), it's important to consider both short-term and long-term perspectives. The short-term outlook, driven by technical analysis indicators, indicates an Uptrend continuation with a 78% probability. On the other hand, fundamental analysis ratings provide insights into the long-term valuation of the stock. By considering these different perspectives, investors can make informed decisions regarding their investment strategies.
Eli Lilly & Co (LLY) shows promising signs of an Uptrend continuation, supported by A.I.dvisor's projections and positive technical indicators. With the stock's winning streak, the bullish Aroon Indicator, and a correlation with MRK, investors may find opportunities for growth and potential price increases in the coming weeks.
LLY in upward trend: price may jump up because it broke its lower Bollinger Band on October 24, 2024
LLY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 32 cases where LLY's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in of 358 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 22, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on LLY as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for LLY turned negative on October 23, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .
LLY moved below its 50-day moving average on October 17, 2024 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for LLY crossed bearishly below the 50-day moving average on October 07, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for LLY entered a downward trend on October 09, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 68, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: LLY's P/B Ratio (67.114) is very high in comparison to the industry average of (5.632). P/E Ratio (131.129) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (1.440) is also within normal values, averaging (3.004). Dividend Yield (0.006) settles around the average of (0.164) among similar stocks. LLY's P/S Ratio (20.121) is very high in comparison to the industry average of (3.643).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor